Wave Life Sciences shares soared more than 70% on Wednesday after the biotech firm said it had successfully edited the RNA of ...

The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and ...

Wave's RNA editing technology appears to have highly potential for the treatment of AATD, a genetic disorder with potential ...

Wave Life Sciences' alpha-1 antitrypsin deficiency candidate WVE-006 succeeded in the first-ever clinical demonstration of ...

Wave claims this is the first clinical data with a therapeutic RNA-editing drug in humans, an achievement that boosted its ...

Mizuho Securities analyst Salim Syed has maintained their bullish stance on WVE stock, giving a Buy rating today. Salim Syed’s rating is ...

Wave Life Sciences (WVE) shares soared 66% after the company announced positive proof-of-mechanism data from a study of ...

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Wave Life Sciences (WVE – Research Report), with ...

Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA ...

Wave Life Sciences' WVE-006 demonstrates first-ever RNA editing in humans for alpha-1 antitrypsin deficiency, showing ...

Wave Life Sciences reports that it has successfully carried out RNA editing in two patients with alpha-1 antitrypsin ...